In a report released on December 28, Thomas Shrader from BTIG maintained a Buy rating on ProMIS Neurosciences (PMN – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $1.15.
Shrader covers the Healthcare sector, focusing on stocks such as Aldeyra Therapeutics, Inmune Bio, and Alector. According to TipRanks, Shrader has an average return of 3.5% and a 37.81% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ProMIS Neurosciences with a $8.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.95 and a one-year low of $0.95. Currently, ProMIS Neurosciences has an average volume of 19.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProMIS Neurosciences (PMN) Company Description:
ProMIS Neurosciences Inc is a biotech company. It is engaged in discovering and developing precision medicine therapeutics for the effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD).
Read More on PMN:
